Dermatitis, Seborrheic: Clinical Trials

11 trials for Dermatitis, Seborrheic, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed. 11 Phase 2, 1 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 211Completed 11
Phase 11Completed 1
Phase 31Completed 1

Follow Dermatitis, Seborrheic: new trials by email Literature Review of Dermatitis, Seborrheic trials Research Report on Dermatitis, Seborrheic

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Ruxolitinib in Seborrheic Dermatitis
Ruxolitinib 1.5% Cream - Seborrheic Dermatitis
Phase 2CompletedIcahn School of Medicine at Mount Sinai452022-11-152025-05-06
Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
ARQ-154 - Seborrheic Dermatitis
Phase 2CompletedArcutis Biotherapeutics, Inc.4082020-06-122024-06-11
Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
Roflumilast Foam 0.3%, Vehicle foam - Seborrheic Dermatitis
Phase 2CompletedArcutis Biotherapeutics, Inc.2262019-12-042023-07-03
Safety and Efficacy of a Topical Scalp Treatment for Dry Scalp Conditions in Children and Adult
Natural Treatment - Dermatitis, Seborrheic, Dry Skin; Eczema
Phase 1 / Phase 2CompletedAnn & Robert H Lurie Children's Hospital of Chicago772019-07-082025-02-24
A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease
Cannabidiol, Placebo - Parkinson Disease
Phase 2CompletedUniversity of Colorado, Denver742018-09-052024-07-23
A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Seborrheic Dermatitis
PAC-14028 cream 0.3%, PAC-14028 cream 1.0%, PAC-14028 cream vehicle - Seborrheic Dermatitis
Phase 2CompletedAmorepacific Corporation752014-02-012016-04-25
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
Test Product 49778, Test Product 10156, Vehicle (placebo) - Seborrheic Dermatitis
Phase 2CompletedMedicis Global Service Corporation2402012-09-012013-01-09
Proof of Concept Study of MTC896 Gel to Reduce Sebum Production on the Forehead of Healthy Male Volunteers
MTC896 Gel - Oily Skin, Seborrhea
Phase 2CompletedMimetica Pty Limited1352010-07-012014-09-12
The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage
Topical oxygen, placebo - Rosacea, Acne Vulgaris
Phase 2CompletedAria Aesthetics Inc.492009-09-012011-06-08
A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis
Elidel, Ketoconazole Cream - Seborrheic Dermatitis
Phase 2CompletedDermatology Specialists Research1132007-05-072022-03-14
Two Topical K40 Formulations in Adults With Seborrhoeic Dermatitis (SD) of the Scalp
K40a, K40b, Placebo - Seborrhoeic Dermatitis of the Scalp
Phase 2 / Phase 3CompletedMoberg Pharma AB982007-02-012010-06-04

Narrower conditions

Acne Vulgaris (1)  ·  Anxiety Disorders (1)  ·  Dermatitis, Atopic (1)  ·  Dyskinesias (1)  ·  Eczema (1)  ·  Marijuana Abuse (1)  ·  Parkinson Disease (1)  ·  Psychotic Disorders (1)  ·  Rosacea (1)  ·  Tremor (1)

Broader conditions

Dermatitis (11)  ·  Sebaceous Gland Diseases (11)  ·  Skin Diseases (11)  ·  Skin Diseases, Eczematous (11)  ·  Skin Diseases, Papulosquamous (11)  ·  Skin and Connective Tissue Diseases (11)  ·  Acneiform Eruptions (1)  ·  Basal Ganglia Diseases (1)  ·  Brain Diseases (1)  ·  Central Nervous System Diseases (1)  ·  Chemically-Induced Disorders (1)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  Genetic Diseases, Inborn (1)  ·  Hypersensitivity (1)  ·  Hypersensitivity, Immediate (1)

Interventions

Cannabidiol (1)  ·  Ketoconazole (1)  ·  Oxygen (1)  ·  pimecrolimus (1)  ·  ruxolitinib (1)

Sponsors

Arcutis Biotherapeutics, Inc. (2)  ·  Amorepacific Corporation (1)  ·  Ann & Robert H Lurie Children's Hospital of Chicago (1)  ·  Aria Aesthetics Inc. (1)  ·  Dermatology Specialists Research (1)  ·  Icahn School of Medicine at Mount Sinai (1)  ·  Medicis Global Service Corporation (1)  ·  Mimetica Pty Limited (1)  ·  Moberg Pharma AB (1)  ·  University of Colorado, Denver (1)

Countries

United States (9)  ·  Canada (1)  ·  Sweden (1)

Top investigators

David Berk, MD (2)  ·  Benjamin Ungar, MD (1)  ·  BeomJoon Kim, Professor (1)  ·  Bernard Goffe, MD (1)  ·  Debra Breneman, MD (1)  ·  Ira Lawrence, MD (1)  ·  Jonathan S Dosik, MD (1)  ·  Lennart Emtestam, MD (1)  ·  Lucy Bilaver, PHD (1)  ·  Maureen Leehey (1)  ·  Steven Kempers, MD (1)  ·  Zoe D Draelos, MD (1)

Results publications

PMID 37133856, PMID 38466972, PMID 41175336